证券代码：688389 证券简称：普门科技 公告编号：2024-041 二、本次限制行权期为2024年8月13日至2024年8月27日，在此期间全部激励 对象将限制行权。 三、公司将按照有关规定通过自主行权主办券商国信证券股份有限公司向中 国证券登记结算有限责任公司上海分公司申请办理限制行权相关事宜。 特此公告。 深圳普门科技股份有限公司董事会 深圳普门科技股份有限公司 关于2021年、2022年股票期权激励计划限制行权期间 的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司股权激励管理办法》《深圳普门科技股份有限公司2021年股 票期权激励计划（草案）》《深圳普门科技股份有限公司2022年股票期权激励计 划（草案）》及中国证券登记结算有限责任公司上海分公司关于股票期权自主行 权的相关规定，结合深圳普门科技股份有限公司（以下简称"公司"）2024年半 年度报告的披露工作计划，现对公司2021年、2022年股票期权激励计划的限制行 权时间公告如下： | 计划名称 | 行权期 | 行权起止日期 | | ...

Financial Performance - The company expects a significant improvement in gross margin for both the fiscal year 2023 and Q1 2024, primarily due to increased sales of in vitro diagnostic reagents and a higher proportion of self-produced raw materials [2] - The gross margin is projected to stabilize at a reasonable level, while the expense ratio will fluctuate based on the development of various product lines [3] Business Growth Expectations - The company anticipates high growth rates in its three main IVD business segments: chemiluminescence, glycosylated hemoglobin, and specific protein, with the latter showing unexpected growth in Q1 2024 [3] - The domestic chemiluminescence market share is substantial, indicating significant growth potential for the company's chemiluminescence business [3] Skin Aesthetic Business - The company officially entered the skin aesthetic market in 2023 and has received positive market feedback since launching its whitening product in November 2023 [4] - There is a large consumer market potential in the skin aesthetic sector, prompting the company to invest in personnel and resources to enhance its marketing capabilities [4] Regulatory Impact - Anti-corruption measures initiated in August 2023 have affected the speed of instrument installations in the luminescence industry, but the company maintains a positive outlook and compliance with regulations [4] Long-term Strategy - The company is focused on becoming a multi-market, multi-business platform, with four key business segments: IVD, clinical medicine, skin aesthetics, and consumer health, supporting its long-term growth [4]

Summary of Conference Call Company/Industry Involved - The conference call pertains to the recent performance and future outlook of a technology company [1] Core Points and Arguments - The meeting is structured to include a presentation by the company's management followed by a Q&A session [1] Other Important but Possibly Overlooked Content - The call aims to provide updates on the company's operational status and strategic direction moving forward [1]

Group 1: Equity Incentive Plans - The company has implemented three phases of equity incentive plans, with performance targets set for a revenue growth rate of 60% and 90% for 2024-2025, and a net profit growth rate of 60% and 90% [2][3] - The company is confident in achieving the performance assessment targets set in the equity incentive plans through continuous product iteration and market channel expansion [2][3] Group 2: Research and Development Investments - In 2023, the company's R&D expenditure was 170 million CNY, accounting for 15% of its revenue [3] - The company focuses on in vitro diagnostics and treatment and rehabilitation, with ongoing R&D in biochemical immunoassay products and clinical medical product upgrades [3] Group 3: Product Development Focus - The in vitro diagnostics product line emphasizes the development of mid-speed luminescence instruments and new testing reagents [3] - The clinical medical product line is upgrading existing products in respiratory critical care, wound treatment, and pain rehabilitation to obtain more international product registrations [3] - The skincare and beauty product line is developing new products focused on anti-aging, skin whitening, and hair growth treatments [3] Group 4: Investor Relations Activity - The investor relations activity involved 10 institutions and 20 participants, held on July 18 and 23, 2024, in Beijing and online [2][4] - The meeting was attended by the board secretary, Lu Man, who addressed investor inquiries regarding the equity incentive plans and R&D projects [2][3]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of RMB 23.08 [16][17]. Core Insights - The company specializes in in vitro diagnostic instruments and reagents, as well as rehabilitation treatment devices, with a dual focus on IVD and aesthetic medicine [17][27]. - The HbA1c testing market in China is primarily dominated by imported brands, indicating significant potential for domestic alternatives [2][16]. - The company has successfully mastered the core technology of High-Performance Liquid Chromatography (HPLC) for HbA1c testing, which is recognized as the gold standard [25][39]. Summary by Sections HbA1c Testing Market - The HPLC method is the mainstream testing methodology for HbA1c, with a 70.1% usage rate among participating laboratories in China [1]. - The global HbA1c testing market is projected to grow from USD 2.3 billion in 2023 to USD 4.7 billion by 2032, with a CAGR of 9% [16][39]. - The company estimates that the HbA1c testing reagent market in China was approximately RMB 1.4 billion in 2021, with a significant portion of testing still reliant on imported brands [16][39]. Product Development and Market Position - The company has developed a comprehensive range of products, including the H100 and H100Plus high-end models, which are positioned for import substitution in both domestic and international markets [25][39]. - The report highlights the company's advanced methodologies and compliance advantages in the aesthetic medicine sector, particularly with its ultrasound V La Mei technology [8][27]. Financial Projections - The company anticipates a CAGR of 33% for HbA1c testing revenue from 2024 to 2026 [16]. - The projected EPS for 2024, 2025, and 2026 is RMB 0.96, RMB 1.21, and RMB 1.52, respectively, reflecting a growth rate of 25% to 26% [17][29]. Competitive Landscape - The report notes that the chemical luminescence market is rapidly expanding, with the company positioned to benefit from domestic substitution opportunities [41]. - The company has established a strong presence in the aesthetic medicine market, with innovative products that are expected to drive significant revenue growth [27][46].

Group 1: Company Overview - Shenzhen Pumen Technology Co., Ltd. adopts a multi-business platform and multi-market development strategy due to the diverse segments within the medical device industry [2] - The company operates in two main business areas: in vitro diagnostics and treatment & rehabilitation, with specific product lines for each [2][3] Group 2: Business Strategy - The company emphasizes the importance of existing technical accumulation and performance support for new business expansions, ensuring synergy in R&D and marketing [3] - Independent management divisions are established for each product line, supported by a public support platform for business and technical development [3] Group 3: Market Potential - The glycosylated hemoglobin (HbA1c) testing market is expected to grow significantly due to the increasing number of diabetes patients and heightened health awareness [3] - The company has developed a series of glycosylated hemoglobin analyzers that cover a wide customer base, enhancing its market presence [3] Group 4: Product Advantages - High-Performance Liquid Chromatography (HPLC) is highlighted as a mainstream technology for glycosylated hemoglobin testing due to its accuracy and ability to indicate the presence of variant hemoglobin [3] - The company's H100Plus analyzer features rapid separation of variants and user-friendly operation, positioning it competitively in the market [3]

深圳普门科技股份有限公司 关于2022年股票期权激励计划首次授予部分股票期权 注销完成的公告 证券代码：688389 证券简称：普门科技 公告编号：2024-040 公司已向中国证券登记结算有限责任公司上海分公司提交了上述股票期权注销 的申请，经中国证券登记结算有限责任公司上海分公司审核确认，上述股票期权注 销事宜已办理完毕。本次股票期权的注销事项不会对公司股本造成影响。 特此公告。 深圳普门科技股份有限公司董事会 2024年7月6日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳普门科技股份有限公司（以下简称"公司"）于2024年5月9日公司召开第 三届董事会第七次会议、第三届监事会第六次会议，审议通过了《关于注销2022年 股票期权激励计划首次授予部分股票期权的议案》；于2024年6月24日召开第三届董 事会第八次会议、第三届监事会第七次会议，审议通过了《关于调整2022年股票期 权激励计划首次授予部分股票期权注销数量的议案》。前述董事会、监事会审议的 注销事项情况如下： 根据《公司2022年股票期权激励计划（草 ...

Group 1: Company Overview - Pumen Technology focuses on two main business segments: in vitro diagnostics and treatment & rehabilitation [2][3] - The company was established in 2008 and aims for differentiated value creation in product development [3] Group 2: Product Strengths - Key products in in vitro diagnostics include electrochemical luminescence, glycosylated hemoglobin, and specific protein series [2][3] - The glycosylated hemoglobin series is based on high-performance liquid chromatography, recognized as the "gold standard" for diabetes testing [3][4] - The H100plus product can separate hemoglobin variants in under one minute, enhancing market share potential [4] Group 3: Market Position - The company holds a leading position in the domestic market for glycosylated hemoglobin analyzers, being the top exporter of Chinese brands from 2019 to 2023 [4] - The market share for glycosylated hemoglobin products is among the top for domestic brands [3] Group 4: Strategic Development - Pumen Technology is expanding its manufacturing capabilities in key economic regions, including a new project in Anhui to enhance production scale and response speed [4] - The company invests approximately 15% of its revenue in research and development [3]

证券代码：688389 证券简称：普门科技 公告编号：2024-039 深圳普门科技股份有限公司 关于2021年、2022年股票期权激励计划 2024年第二季度自主行权结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次行权数量： 1、深圳普门科技股份有限公司（以下简称"公司"）2021年股票期权激励 计划（以下简称"2021年激励计划"）首次授予股票期权第二个行权期可行权数 量为3,502,500份，实际可行权期为2023年10月25日至2024年10月10日（行权日须 为交易日）。2024年4月1日至2024年6月30日期间，累计行权并完成股份过户登 记数量为12,630股，占本次可行权总量的0.36%。截至2024年6月30日，累计行权 并完成股份过户登记数量386,445股，占本次可行权总量的11.03%。 2、公司2021年激励计划预留授予股票期权第二个行权期可行权数量为 682,500份，实际可行权期为2024年6月7日至2025年1月20日（行权日须为交易日）。 202 ...

| 序 | 产品名称 | 分类 | 证书 | 预期用途 | | --- | --- | --- | --- | --- | | 号 | | | 有效期至 | | | 1 | immunoassay) | Class B | 2029-06-23 | | | | Thyroid stimulating hormone (Electrochemiluminescence | | | | | | 促甲状腺素测定试剂盒（电化学发光 | | | | | | 法） | | | | | | 25-OH Vitamin D Total | | | 用 于 筛 查 、 | | 2 | (Electrochemiluminescence Immunoassay) | Class B | 2029-06-23 | 测 定 或 监 测 生理标记物 | | | 25-羟基维生素 D 测定试剂盒（电化学 | | | | | | 发光法） | | | | | 3 | Interleukin-6 (Electrochemiluminescence Immunoassay) | Class B | 2029-06-23 | | | | 白介素 ...